Chronic myelomonocytic leukemia (CMML) is a rare type of leukemia that develops from monocytes, which are white blood cells that help the immune system fight infection. In CMML, the body produces too many abnormal, immature monocytes that crowd out healthy blood cells. It's more common in men and adults over 60. Survival Show Full Answer
Chronic myelomonocytic leukemia (CMML) is a rare type of leukemia that develops from monocytes, which are white blood cells that help the immune system fight infection. In CMML, the body produces too many abnormal, immature monocytes that crowd out healthy blood cells. It's more common in men and adults over 60. Survival after a CMML diagnosis varies widely from person to person. Here are some key factors that influence outlook:
- Age at diagnosis
- Blood cell counts
- Genetic changes in CMML cells
- Percentage of blast cells in blood and bone marrow
- CMML subtype — the dysplastic subtype (MD-CMML) generally has a more positive outlook than the proliferative subtype (MP-CMML)
People in the lowest-risk group may live around 8 years, while those in the highest-risk group may live around 16 months. A specialist can give a much clearer picture based on individual factors. There are several treatment options available for CMML. A doctor will consider overall health, symptoms, and how quickly the condition is progressing when recommending a plan.
- Bone marrow transplant — the only potential cure, but carries serious risks and isn't suitable for everyone
- Chemotherapy — can help normalize blood cell counts and reduce symptoms, but doesn't cure CMML
- Radiation therapy or spleen removal — used when the spleen becomes enlarged
- Supportive care — includes blood transfusions and growth factors to manage low blood cell counts
- Clinical trials — new treatments are being researched; worth discussing with a hematologist/oncologist
It's worth noting that about 15–30% of people with CMML may later develop a more aggressive form of leukemia, so staying closely monitored by a specialist is really important.
August 27
Join
Your Privacy Choices
